Reference
Kalen E, et al. Demyelinating events following anti-tumor necrosis factor alpha therapy: Rare but challenging to treat. European Journal of Neurology 29: 2047-2055, No. 7, Jul 2022. Available from: URL: http://doi.org/10.1111/ene.15318
Rights and permissions
About this article
Cite this article
Adalimumab/etanercept/infliximab. Reactions Weekly 1918, 25 (2022). https://doi.org/10.1007/s40278-022-20482-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-022-20482-6